- Home
- ACDC vs SNDX Comparison
ACDC vs SNDX Comparison
Compare ACDC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACDC
- SNDX
- Stock Information
- Founded
- ACDC 2014
- SNDX 2005
- Country
- ACDC United States
- SNDX United States
- Employees
- ACDC N/A
- SNDX N/A
- Industry
- ACDC Oilfield Services/Equipment
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- ACDC Energy
- SNDX Health Care
- Exchange
- ACDC Nasdaq
- SNDX Nasdaq
- Market Cap
- ACDC 1.3B
- SNDX 1.1B
- IPO Year
- ACDC 2022
- SNDX 2016
- Fundamental
- Price
- ACDC $6.51
- SNDX $9.98
- Analyst Decision
- ACDC Sell
- SNDX Strong Buy
- Analyst Count
- ACDC 4
- SNDX 11
- Target Price
- ACDC $6.50
- SNDX $34.00
- AVG Volume (30 Days)
- ACDC 368.7K
- SNDX 1.8M
- Earning Date
- ACDC 08-07-2025
- SNDX 08-04-2025
- Dividend Yield
- ACDC N/A
- SNDX N/A
- EPS Growth
- ACDC N/A
- SNDX N/A
- EPS
- ACDC N/A
- SNDX N/A
- Revenue
- ACDC $2,209,700,000.00
- SNDX $43,722,000.00
- Revenue This Year
- ACDC N/A
- SNDX $431.08
- Revenue Next Year
- ACDC N/A
- SNDX $105.38
- P/E Ratio
- ACDC N/A
- SNDX N/A
- Revenue Growth
- ACDC N/A
- SNDX N/A
- 52 Week Low
- ACDC $3.83
- SNDX $8.58
- 52 Week High
- ACDC $10.70
- SNDX $22.98
- Technical
- Relative Strength Index (RSI)
- ACDC 34.86
- SNDX 52.38
- Support Level
- ACDC $7.61
- SNDX $9.42
- Resistance Level
- ACDC $8.30
- SNDX $10.75
- Average True Range (ATR)
- ACDC 0.51
- SNDX 0.59
- MACD
- ACDC -0.13
- SNDX 0.07
- Stochastic Oscillator
- ACDC 8.10
- SNDX 55.23
About ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. Its operations are focused in West Texas, East Texas/Louisiana, South Texas, Oklahoma, Uinta, and Appalachian. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.